The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)
A Double-blind, Placebo Controlled, 12-week Treatment Trial in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Males in good general health 50 years of age and older, with symptoms of moderate to severe benign prostatic hyperplasia.
- 120 patients: Study arm- min. 80 patients Placebo arm- min. 40 patients Final Aim for Stat. Sig.: 75% of recruitment group (90 patients)
- Duration - 12 weeks with 3 visits: 0,6,12 weeks
The following procedures are utilized:
- Physical exams - visit 1,3.
- Drugs/food supplement usage questionnaire - visit 1.
- Product supply Control - visit 1,2.3
- Clinical laboratory tests : psa, cbc, bun - visit 1,3.
- Uroflowmetry test visit - visit 1,3.
- IPSS- International Prostate Symptom Score - questionnaire - visit 1, 3.
- IIEF questionnaire - visit 1, 3.
- dosage: 1 capsule twice daily (morning & evening) can be taken with or without food
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ohad Shoshani, MD
- Phone Number: +972-54-9577567
- Email: ohadsh10@gmail.com
Study Contact Backup
- Name: Adi Raz
- Phone Number: +972-52-7390972
- Email: adi@se-curepharma.com
Study Locations
-
-
-
Petach Tikva, Israel, 4941492
- Recruiting
- Rabin Medical Center - Clalit Health Services
-
Contact:
- Ohad Shoshany, MD
- Phone Number: +972-54-9577567
- Email: ohadsh10@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Males in good general health at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia
Exclusion Criteria:
- Inability to complete the questionnaire.
- Patients with or suspected of having prostate cancer.
- Patients who have undergone a surgical procedure in the past year and / or who have taken medications or supplements in the past six months to treat BPH.
- Patients treated with drugs for kidney / urinary tract problems.
- Allergy to soy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brizo SC012
A capsule containing 400 mg.
SC012 (unique soy extract) TWICE A DAY : MORNING , EVENING.
|
A capsule containing 400 mg.
SC012 (unique soy extract)
|
|
Placebo Comparator: PLACEBO
A capsule containing 400 mg OF PLACEBO, TWICE A DAY: MORNING , EVENING.
|
Comprecel microcrystalline cellulose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improved index in the IPSS test
Time Frame: 12 weeks
|
Improvement by 3 points and with a significance of P< 0.05.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improve UROFLOWMETRY test
Time Frame: 12 WEEKS
|
Improve from personal baseline in UROFLOWMETRY test at Week 12 .
|
12 WEEKS
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ohad Shoshani, MD, Rabin Medical Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0615-21-RMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.